The estimated Net Worth of Mary B Esq Templeton is at least $455 Tausend dollars as of 22 May 2020. Ms. Templeton owns over 1,103 units of Windtree Therapeutics stock worth over $3,459 and over the last 6 years she sold WINT stock worth over $0. In addition, she makes $451,907 as Senior Vice President und General Counsel and Corporate Secretary at Windtree Therapeutics.
Mary has made over 1 trades of the Windtree Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently she bought 1,103 units of WINT stock worth $7,997 on 22 May 2020.
The largest trade she's ever made was buying 1,103 units of Windtree Therapeutics stock on 22 May 2020 worth over $7,997. On average, Mary trades about 552 units every 0 days since 2019. As of 22 May 2020 she still owns at least 1,134 units of Windtree Therapeutics stock.
You can see the complete history of Ms. Templeton stock trades at the bottom of the page.
Mary B. Templeton Esq. serves as Senior Vice President, General Counsel and Corporate Secretary of the Company. Ms. Templeton brings to us 40 years of legal and executive experience. Ms. Templeton previously held senior executive positions in the financial services industry, including as Senior Vice President and General Counsel of The Charles Schwab Corporation and as Senior Vice President and General Counsel of The Sequor Group Inc. (owned by Security Pacific Corporation) and in private practice in Philadelphia and New York. Prior to that, at Charles Schwab & Co., Ms. Templeton led development of the first broker-operated mutual fund marketplace, and, at Bradford Trust Company (New York), the first for-profit clearing corporation registered with the SEC. Ms. Templeton received a B.A. degree from Chatham University, where she is a member of the Board of Trustees, where she served as Editor-in-Chief of the Law Journal. She is a member of the Bar Associations of Pennsylvania and New York.
As the Senior Vice President und General Counsel and Corporate Secretary of Windtree Therapeutics, the total compensation of Mary Templeton at Windtree Therapeutics is $451,907. There are 5 executives at Windtree Therapeutics getting paid more, with Craig Fraser having the highest compensation of $1,063,640.
Mary Templeton is 73, she's been the Senior Vice President und General Counsel and Corporate Secretary of Windtree Therapeutics since 2011. There are no older and 16 younger executives at Windtree Therapeutics.
Mary's mailing address filed with the SEC is 2600 KELLY ROAD, SUITE 100, WARRINGTON, PA, 18976.
Over the last 6 years, insiders at Windtree Therapeutics have traded over $1,982,541 worth of Windtree Therapeutics stock and bought 6,849,036 units worth $20,224,921 . The most active insiders traders include James Huang, Pharmaceutical Holdings Ltd... und Ii Investments Ltd Lph. On average, Windtree Therapeutics executives and independent directors trade stock every 24 days with the average trade being worth of $425,323. The most recent stock trade was executed by Craig Fraser on 27 September 2023, trading 2,500 units of WINT stock currently worth $2,550.
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
Windtree Therapeutics executives and other stock owners filed with the SEC include: